Elaine Tan1, Bassel El-Rayes2,3. 1. Department of Internal Medicine, Emory University School of Medicine, 100 Woodruff Circle Suite, 327, Atlanta, GA, 30322, USA. estan@emory.edu. 2. Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA. 3. Winship Cancer Institute, Emory University, 1365 Clifton Road, Atlanta, GA, 30322, USA.
Abstract
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) continues to be one of the most aggressive and lethal diseases in the world. The success of immunotherapy in other types of malignancy has led to further trials to understand better the role of immunotherapy in PDAC. However, initial studies with immunotherapy, namely, the checkpoint inhibitors, in PDAC have not been met with the same outcomes. The purpose of this review is to identify and discuss the various resistance mechanisms of PDAC to immunotherapy (pancreatic stroma, genetic predisposition/epigenetics, and the immune inhibitory cells, cytokines, soluble factors, and enzymes that comprise the tumor microenvironment) and the solutions currently being studied to overcome them. CONCLUSIONS: Various preclinical and early clinical studies have shown that immunotherapy, especially checkpoint inhibitors, in PDAC may be efficacious as part of a multi-modal treatment, in combination with other therapies that target these resistance mechanisms. Several clinical trials are ongoing to explore this concept further.
BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) continues to be one of the most aggressive and lethal diseases in the world. The success of immunotherapy in other types of malignancy has led to further trials to understand better the role of immunotherapy in PDAC. However, initial studies with immunotherapy, namely, the checkpoint inhibitors, in PDAC have not been met with the same outcomes. The purpose of this review is to identify and discuss the various resistance mechanisms of PDAC to immunotherapy (pancreatic stroma, genetic predisposition/epigenetics, and the immune inhibitory cells, cytokines, soluble factors, and enzymes that comprise the tumor microenvironment) and the solutions currently being studied to overcome them. CONCLUSIONS: Various preclinical and early clinical studies have shown that immunotherapy, especially checkpoint inhibitors, in PDAC may be efficacious as part of a multi-modal treatment, in combination with other therapies that target these resistance mechanisms. Several clinical trials are ongoing to explore this concept further.
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: K Narumi; T Udagawa; A Kondoh; A Kobayashi; H Hara; Y Ikarashi; S Ohnami; F Takeshita; T Ochiya; T Okada; M Yamagishi; T Yoshida; K Aoki Journal: Gene Ther Date: 2011-05-26 Impact factor: 5.250
Authors: Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg Journal: J Immunother Date: 2010-10 Impact factor: 4.456
Authors: Gregory L Beatty; Elena G Chiorean; Matthew P Fishman; Babak Saboury; Ursina R Teitelbaum; Weijing Sun; Richard D Huhn; Wenru Song; Dongguang Li; Leslie L Sharp; Drew A Torigian; Peter J O'Dwyer; Robert H Vonderheide Journal: Science Date: 2011-03-25 Impact factor: 47.728
Authors: Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Brian M Wolpin; Aram F Hezel; Thomas Abrams; Lawrence S Blaszkowsky; Jeffrey A Meyerhardt; Jennifer A Chan; Peter C Enzinger; Brittany Allen; Jeffrey W Clark; David P Ryan; Charles S Fuchs Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Milind M Javle; Rachna T Shroff; Henry Xiong; Gauri A Varadhachary; David Fogelman; Shrikanth A Reddy; Darren Davis; Yujian Zhang; Robert A Wolff; James L Abbruzzese Journal: BMC Cancer Date: 2010-07-14 Impact factor: 4.430
Authors: Nabeel Merali; Tarak Chouari; Kayani Kayani; Charles J Rayner; José I Jiménez; Jonathan Krell; Elisa Giovannetti; Izhar Bagwan; Kate Relph; Timothy A Rockall; Tony Dhillon; Hardev Pandha; Nicola E Annels; Adam E Frampton Journal: Cancers (Basel) Date: 2022-02-17 Impact factor: 6.639
Authors: Tamas A Gonda; Jarwei Fang; Martha Salas; Catherine Do; Emily Hsu; Anna Zhukovskaya; Ariel Siegel; Ryota Takahashi; Zoila A Lopez-Bujanda; Charles G Drake; Gulam A Manji; Timothy C Wang; Kenneth P Olive; Benjamin Tycko Journal: Cancer Res Date: 2020-08-14 Impact factor: 13.312